Trump Administration Moves State-Licensed Medical Marijuana To Schedule III

The Trump administration this week moved state-licensed medical marijuana to Schedule III under federal law, loosening restrictions that had treated it as more tightly controlled. Under Schedule III, drugs are considered to have accepted medical uses and lower abuse potential than Schedule I or II substances, which could ease research restrictions and prescribing hurdles. The shift may also reduce federal interference with state programs and make it easier for banks to handle marijuana-related funds, though separate legal and tax barriers could remain.

Advocates and some lawmakers praised the move as a long-awaited step toward reconciling federal and state policies, emphasizing benefits for patients, researchers, and businesses. Others warned that it stops short of full legalization and that enforcement discretion, interstate commerce rules, and international treaty obligations could still limit impact. Lawmakers, regulators, and courts may now face a new wave of legal and administrative questions about implementation, banking access, and tax treatment as the change is rolled out.